Russian Federation reportedly has two candidate vaccines being considered for approval: Vektor's and another developed by the Moscow-based Gamaleya Institute in cooperation with the Defense Ministry.
On the 42nd day after the first vaccination, the volunteers returned to the hospital and underwent an in-depth medical examination and diagnosis, it said.
This will hasten the development of the COVID-19 vaccine.
Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding the needed immune response into cells.
"An urgent meeting was held by the subject expert committee on COVID-19 on Friday to consider SII's application".
The Drugs Controller General of India (DCGI) on Monday (August 3, 2020) gave approval to the Serum Institute of India in Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.
Swift's Folklore tops the charts both sides of Atlantic
The musician beat BTS's " Map of the Soul " that has sold 574,000 units since its release in February 2020. The album dethroned Juice WRLD's album " Legends Never Die " to claim the number one position.
USA experimental COVID-19 vaccine protects airways in nonhuman primates
Pfizer and BioNTech's first vaccine targeted a piece of the spike protein , a structure the virus uses to infect human cells. Clinical trials on another 1,600 people will start after the registration and will continue along with the production.
TikTok thanks users as Trump vows to ban app
The proposal values TikTok at about $50 billion, but some ByteDance executives believe the app is worth more than that. Republicans have accused the company of trying to "meddle" in the U.S. presidential election.
According to the study design, each subject will be given two doses four weeks apart (the first dose on day one and the second on day 29), after which safety and immunogenicity will be assessed at predefined intervals. "The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to Phase 3 clinical trials", a senior official said. Around 1,600 people above 18 years of age will participate in the trials across 17 selected sites.
Last month, Russian Federation was accused by officials in the U.S., Canada and Britain of trying to hack and steal coronavirus vaccine data.
Currently, the country is said to be initially planning serial production of the first domestic vaccine developed by the Gamaleya National Research Center of Epidemiology and Microbiology by September, TASS, a Russian agency reported.
In fact, the cost and effort alone is likely to take years as vaccines are required to go through multi-stage clinical trial processes to ensure it's safe for everyone, particularly those who are high-risk or have underlying conditions. The candidate, is however, yet to complete its trials.
RDIF has been involved in funding the country's vaccine research.
Sanofi-GlaxoSmithKline: Sanofi and GlaxoSmithKline have said that they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine for the 27-country European Union.